Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

However, the effect of cataract surgery on other measures of dry eye is unclear, with inconsistent outcomes across studies. Researchers conducted a systematic review of 20 observational studies ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

He cited the prolonged dry weather, lack of rainfall and high dust levels as contributing factors and urged citizens to take precautions to protect their kids. Talking to a private news channel Dr ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease. Under the terms of the option ...